Martin Shkreli

Shkreli’s quantum view is both technological and business-model bearish: today’s machines accelerate one narrow class of problems while losing badly at ordinary computing. He argues that quantum’s real advantage is moving integer factorization and elliptic-curve discrete logarithms from exponential to polynomial time—not sorting or general computation. Current systems run at hundreds or thousands of hertz, lack quantum RAM, and, in his testing, “can’t multiply 300 by 200.” He says companies spending hundreds of millions on the field are betting that “something might come of this someday.”

The host’s strongest counterargument—that quantum may simply be at its transistor-era beginning—does not change Shkreli’s investment conclusion. He concedes the technology could eventually work, then asks whether investors would have wanted punch cards, vacuum tubes, or ferrite-core memory: important stages whose owners largely disappeared. He has lost millions shorting quantum-computing companies but jokes that he “gained billions in insights,” conceding that market timing is the hard part.

His preferred compute disruption is analog optical computing, because AI workloads spend “99.9%” of their time multiplying matrices. Shkreli says a 1,000-by-1,000 matrix multiplication takes roughly one billion operations on an Nvidia machine, whereas multiplication in light can occur instantly. He is exploring photonic cores and predicts that within 20 years H100s, B100s, and B200s will “end up in the trash.”

That technological bearishness does not translate into a clean Nvidia short: Shkreli owns semiconductor stocks and is still positioned for AI upside. Jevons’ paradox may absorb efficiency gains, but he insists a transformer that is 1,000 times more efficient would still be “bad for Nvidia”; whether demand then expands one million-fold is unresolved. His warning is historical: in 2000, he probably would also have bought Yahoo and Cisco.

Big Pharma’s blind spot, in Shkreli’s telling, is the mispricing of discarded molecules rather than a shortage of scientific ideas. He bought a Bristol-Myers drug for $2 million and says the same company is now public and worth $6 billion; sparsentan was redirected from hypertension to FSGS, eventually giving roughly 30,000 people who had never had medication access to an approved treatment. “I can be a good person too,” he says, while calling this “a great way to make a billion dollars.”

Shkreli rejects near-term AI drug-discovery hype but remains extremely bullish on the market for machine intelligence. He calls claims that AI will develop drugs within five years “complete nonsense” and says he does not think there will be a single AI-related drug in the next 10 years, yet sees effectively unlimited demand for intelligence and labor. His endpoint is not merely chatbots but platforms building whole businesses—“an entire S&P 500” inside OpenAI, Anthropic, or their successors.

Prison changed Shkreli’s account of his own failure from overidentification with achievement to a more grounded view of himself. He says refusing to admit he was not the world’s best hedge-fund manager—even though he was a strong entrepreneur—“got me to prison.” His broader lesson is that gifted people can turn a felt obligation to achieve something enormous into self-destruction, while prison revealed the ordinary needs shared beneath status: missed friends and loved ones, and the wish to be a good parent.

Shkreli’s highest-conviction AI call is that drug discovery is bottlenecked by choosing the biological target, not generating the molecule. He estimates invention at roughly 10% of the process, human testing at the other 90%, and clinical trials at 50-70% of total cost; brute-force screening of 100 billion molecules is already feasible, while screening 100 trillion or 100 quadrillion may add little. The real opportunity is a “GPT pharmaceuticals” that reads roughly 36-38 million PubMed papers, ranks overlooked targets, and tells humans what to build.

His strongest example is BTK, where the valuable insight sat in published research for 15-20 years before anyone translated it into a major drug strategy. Shkreli argues that an LLM could connect such papers to clinical possibilities across every human protein, addressing the “human intelligence” constraint that forced his team of 18—and Vivek Ramaswamy’s team of roughly 80—to manually scan medical literature. “The intelligence goes in the front end,” while much of the downstream chemistry is comparatively deterministic.

The investable constraint in biopharma remains scarce targets, extreme capital intensity, and ten-year development cycles—not a shortage of molecule-generation tools. Only about 40 drugs receive FDA approval annually by Shkreli’s count, perhaps 20 of them meaningfully innovative, while competitors swarm every promising target. In his first drug company, he says he retained about 10% of the equity; software may reach product-market fit for less than a single $1 million mouse experiment. His ketamine program reinforced the risk: strong Yale data became merely better than SSRIs, not the expected “miracle,” in Phase 3.

Shkreli’s finance startup found millions of dollars in revenue after abandoning forced AI positioning and building a dense, low-latency financial suite for traders. After earlier attempts including TTS and consumer medical AI, the still-unreleased beta “went off the charts”; its intentionally crowded interface is “Vim for finance,” optimized for people spending 8-10 hours daily navigating securities. His near-term AI wedge is breaking-news interpretation: an LLM could have reacted to Hims’s GLP-1 announcement in a second, though any edge may diffuse across Wall Street within six months to a year.

He thinks AI enthusiasm may expand into “one of the bubbles to end all bubbles,” but does not think today’s market yet displays dot-com-style mania. He thinks OpenAI will go public near a $1 trillion market cap, supported by real revenue and productivity gains as companies such as Verizon or Procter & Gamble save a billion dollars here and there. He even calls 100 times sales potentially rational for fast-growing SaaS; the danger signal would be indiscriminate funding, while opaque private marks currently make price discovery difficult to assess.

The failed AI products taught him that technical novelty is not a substitute for distribution, workflow integration, or willingness to pay. TTS may be only a “billion-ish” aggregate market vulnerable to open-source local models, while his AI-doctor product drew usage but little revenue and risked competing directly with Grok and other general foundation models. His conclusion tracks the Nuance precedent: the durable business may be packaging technology into a physician workflow, not owning the base model.

On the price controversy and criminal case, Shkreli offered a categorical self-defense rather than a concession, while Biewald preserved the core moral pushback. Shkreli said he would not let a patient go without the drug, defended million-dollar pricing for a fatal pediatric disease with perhaps 500 patients, and described the fraud prosecution as “lawfare”; he says his hedge fund returned 4-5x capital and no investor lost money, while acknowledging convictions for misleading investors and maintaining innocence. He says he received a seven-year sentence, of which one typically serves roughly five, read 300-400 books, and advised Sam Bankman-Fried—whom he described as facing 25 years—that prison requires cultural flexibility: “You just have to roll with the punches.”